Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;44(10):1009-1011.
doi: 10.1097/INF.0000000000004920. Epub 2025 Aug 22.

Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season

Isabel González-Bertolín  1 , Sonia Alcolea  1   2   3 , Patricia Alonso  4 , María Arroyas  4   5 , Isabel Fernández Castiella  1 , Iciar Echavarren  1 , Maria Iglesias-Caballero  6 , Inmaculada Casas  7   6 , María Luz García-García  8   7   5 , Cristina Calvo  7   9   2   3
Affiliations

Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season

Isabel González-Bertolín et al. Pediatr Infect Dis J. .

Abstract

Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy.

Keywords: antibody-dependent enhancement; immunization; nirsevimab; respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Shi T, McAllister DA, O’Brien KL, et al. ; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–958. - PMC - PubMed
    1. Hammitt LL, Dagan R, Yuan Y, et al. ; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837–846. - PubMed
    1. van Erp EA, Luytjes W, Ferwerda G, et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548. - PMC - PubMed
    1. Taylor A, Foo SS, Bruzzone R, et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 2015;268:340–364. - PMC - PubMed
    1. Ministerio de Sanidad: recomendaciones de uso de nirsevimab en la temporada 2024-25. Available at: https://vacunasaep.org/profesionales/noticias/ministerio-de-sanidad-reco.... Accessed April 3, 2025.

MeSH terms

Substances